US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Super League Gaming Inc.

0.2380

-0.0066-2.70%

Post-market: 0.2349-0.0031-1.30%19:59 EDT

Volume:188.60K

Turnover:45.25K

Market Cap:4.23M

PE:-0.05

High:0.2600

Open:0.2510

Low:0.2350

Close:0.2446

Loading ...

Overview Company News Filings

Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates

Press Release: Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024

BRIEF-Infinite Reality reports 9.2% stake in Super League Enterprise

Infinite Reality, Inc. Reports 9.2% Stake in Super League Enterprise, Inc. as of October 29, 2024 - SEC Filing

THOMSON REUTERS

Is Caribou Biosciences (CRBU) a Promising Gene Editing Stock?

Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update

BRIEF-Super League Completes Initial Stage Of Equity Exchange Transfer With Infinite Reality

Super League Enterprise announces iR acquires 1.22M shares of common stock

Super League Completes Initial Stage of Equity Exchange Transfer With Infinite Reality

THOMSON REUTERS

BRIEF-Super League Announces $1 Mln Registered Direct Investment From Infinite Reality

Super League Enterprise announces $1M direct investment from Infinite Reality

Super League Announces $1 Million Registered Direct Investment From Infinite Reality

THOMSON REUTERS

Press Release: Super League Announces $1 Million Registered Direct Investment From Infinite Reality

ImmuneOnco Biopharma SLC Drug Administered to First Patient in Clinical Trial; Shares Up 16%

MT Newswires Live

ImmuneOnco Biopharmaceuticals Advances with SLE Treatment Trial

Biogen Inc. (BIIB): An Oversold Large Cap Stock To Buy Now

Mega-projects like Changi Airport T5 could drive up construction costs in S’pore next year: Surbana Jurong

Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside

Autolus Therapeutics (AUTL): High-Growth UK Stock in Cancer Therapy

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SLE/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SLE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLE\",,,,,undefined,":{"symbol":"SLE","market":"US","secType":"STK","nameCN":"Super League Gaming Inc.","latestPrice":0.238,"timestamp":1743624000000,"preClose":0.2446,"halted":0,"volume":188595,"hourTrading":{"tag":"盘后","latestPrice":0.2349,"preClose":0.238,"latestTime":"19:59 EDT","volume":7841,"amount":1739.7832,"timestamp":1743638385056},"delay":0,"floatShares":12432300,"shares":17776170,"eps":-4.481745,"marketStatus":"Not Yet Opened","change":-0.0066,"latestTime":"04-02 16:00:00 EDT","open":0.251,"high":0.26,"low":0.235,"amount":45245.69254755,"amplitude":0.102208,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.481745,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1743667200000},"marketStatusCode":0,"adr":0,"listingDate":1551157200000,"exchange":"NASDAQ","adjPreClose":0.2446,"preHourTrading":{"tag":"盘前","latestPrice":0.2581,"preClose":0.2411,"latestTime":"08:27 EDT","volume":1743,"amount":450.24391649999995,"timestamp":1743596831410},"postHourTrading":{"tag":"盘后","latestPrice":0.2349,"preClose":0.238,"latestTime":"19:59 EDT","volume":7841,"amount":1739.7832,"timestamp":1743638385056},"volumeRatio":0.674276},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SLE\",,,,,undefined,":{"symbol":"SLE","floatShares":12432300,"roa":"-54.85%","roe":"-244.57%","lyrEps":-13.672882,"volumeRatio":0.674276,"shares":17776170,"dividePrice":0,"high":0.26,"amplitude":0.102208,"preClose":0.2446,"low":0.235,"week52Low":0.22,"pbRate":"1.20","psRate":"0.19","week52High":2.2251,"institutionHeld":0,"latestPrice":0.238,"eps":-4.481745,"divideRate":0,"volume":188595,"delay":0,"ttmEps":-4.481745,"open":0.251,"prevYearClose":0.6175,"prevWeekClose":0.266,"prevMonthClose":0.235,"prevQuarterClose":0.235,"fiveDayClose":0.3884,"twentyDayClose":0.4,"sixtyDayClose":0.7584},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SLE\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2481954624","title":"Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2481954624","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481954624?lang=en_us&edition=fundamental","pubTime":"2024-11-07 05:00","pubTimestamp":1730926800,"startTime":"0","endTime":"0","summary":"ADI-001 Phase 1 clinical trial expanded to include a total of six autoimmune disease indications; preliminary clinical data in lupus nephritis  anticipated in 1H25. Strong balance sheet with $202.1 million in cash, cash equivalents and short-term investments as of September 30, 2024. REDWOOD CITY, Calif. & BOSTON, November 06, 2024----Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the third quarter ended September 30, 2024.FDA clearance of IND amendment to evaluate ADI-001 in IIM and SPS. In October 2024, Adicet announced that the U.S. Food and Drug Administration  cleared the Company’s Investigational New Drug  amendment application to evaluate ADI-001 in IIM and SPS as part of the Phase 1 clinical trial in autoimmune diseases.Presented ADI-001 clinical biomarker data demonstrating robust tissue trafficking an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adicet-reports-third-quarter-2024-210000809.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ACR","BK4230","BK4139","IIM","BK4110","SLE","BK4077","CAR","BK4022","ACET"],"gpt_icon":0},{"id":"2481122502","title":"Press Release: Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2481122502","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481122502?lang=en_us&edition=fundamental","pubTime":"2024-11-05 22:05","pubTimestamp":1730815500,"startTime":"0","endTime":"0","summary":"-- Expansion of Phase 1 CALiPSO-1 trial of CNTY-101 in autoimmune disease to include diffuse cutaneous systemic sclerosis and idiopathic inflammatory myopathy --. -- Overall response rate  of 83% observed at CNTY-101 Dose Level 3B alongside a favorable safety profile in patients with r/r B-cell lymphomas in Phase 1 ELiPSE-1 study --. -- CNTY-101 shows persistence upon repeated cell dosing at Dose Level 3B, consistent with the anticipated protective activity of Century's proprietary Allo-Evasion technology --. -- Ended third quarter 2024 with cash, cash equivalents, and investments of $244.7 million; organizational efficiencies extend expected cash runway into second half of 2026 --. PHILADELPHIA, Nov. 05, 2024  -- Century Therapeutics, Inc. , an innovative biotechnology company developing induced pluripotent stem cell -derived cell therapies in immuno-oncology and autoimmune disease, today reported financial results and business highlights for the third quarter ended September 30, 2024","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","LENZ","TM","BK4006","IE00B66KJ199.SGD","BK4505","IE00B19Z4B17.USD","BK4588","IE00B7SZL793.SGD","CRS","BK4539","SLE","03160","BK4099","BK4077","CNBKA","IPSC","BK4555","IE0031619046.USD","IIM"],"gpt_icon":1},{"id":"2480301122","title":"Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2480301122","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480301122?lang=en_us&edition=fundamental","pubTime":"2024-11-04 20:00","pubTimestamp":1730721600,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Nov. 04, 2024  -- Cullinan Therapeutics, Inc. , a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced the upcoming presentation of preclinical data for CLN-978, a novel CD19xCD3 bispecific T cell engager, at American College of Rheumatology  Convergence 2024, taking place in Washington, D.C. from November 14-19, 2024.“These preclinical data show that CLN-978 is a highly potent T cell engager that leads to deep B cell depletion, supporting the broad development of CLN-978 as a potential new therapeutic option for patients with autoimmune diseases,” said Jeffrey Jones, MD, MBA, Chief Medical Officer, Cullinan Therapeutics. “We look forward to continued collaboration with investigators and the patient community as we initiate our global Phase 1 clinical trial of CLN-978 in systemic lupus erythematosus and deliver on our mission to bring new standards of care to patients.”","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/8YHWqKJllJrX4H7ePTYJSg--~B/aD02Mjk7dz0xMjAxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/da6db52b96baf72a99e6f5ae010de81c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/8YHWqKJllJrX4H7ePTYJSg--~B/aD02Mjk7dz0xMjAxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/da6db52b96baf72a99e6f5ae010de81c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cullinan-therapeutics-present-preclinical-data-120000509.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SLE","BK4139","BK4077","CGEM","ACR","BK4110"],"gpt_icon":0},{"id":"2480866235","title":"BRIEF-Infinite Reality reports 9.2% stake in Super League Enterprise","url":"https://stock-news.laohu8.com/highlight/detail?id=2480866235","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480866235?lang=en_us&edition=fundamental","pubTime":"2024-11-02 06:07","pubTimestamp":1730498859,"startTime":"0","endTime":"0","summary":"Nov 1 (Reuters) - Super League Enterprise Inc   :   * INFINITE REALITY, INC. REPORTS 9.2% STAKE IN SUPER LEAGUE ENTERPRISE, INC. AS OF OCTOBER 29, 2024 - SEC FILINGSource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","BK4077"],"gpt_icon":0},{"id":"2480868307","title":"Infinite Reality, Inc. Reports 9.2% Stake in Super League Enterprise, Inc. as of October 29, 2024 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2480868307","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480868307?lang=en_us&edition=fundamental","pubTime":"2024-11-02 05:03","pubTimestamp":1730494987,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241101:nFWN3M8140:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4077","SLE"],"gpt_icon":0},{"id":"2479773696","title":"Is Caribou Biosciences (CRBU) a Promising Gene Editing Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2479773696","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479773696?lang=en_us&edition=fundamental","pubTime":"2024-10-31 15:53","pubTimestamp":1730361184,"startTime":"0","endTime":"0","summary":"We recently published a list of 10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Caribou Biosciences, Inc.  stands against other most promising gene editing stocks to buy according to hedge funds.The pharmaceutical industry remains a hub of patent innovation, driven by evolving treatment paradigms, unmet medical needs, and the rising influence of technologies like pharmacogenomics, digital therapeutics, and artificial intelligence. At the forefront of modern biotechnology are gene therapy and gene editing. Gene therapies correct genetic defects by introducing new genetic material at the cellular level, often by adding a functioning copy of a gene.That said, the industry is still poised for significant growth. According to a report by Precedence Research, the global genome editing market, valued at $7.98 billion in 2023, is expected to grow to $9.33 billion in 2024 and reach","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/FnZlZmCrZosTKPjEDab71A--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/72592e85e809e9871ee43a59e194ffb9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/FnZlZmCrZosTKPjEDab71A--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/72592e85e809e9871ee43a59e194ffb9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/caribou-biosciences-crbu-promising-gene-075304345.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":[".IXIC","TQQQ","LU1861558580.USD","SLE","BK4588","BK4556","BK4585","MNQmain","PSQ","LU1861559042.SGD","QLD","BK4077","SQQQ","NQmain","BK4539","BK4139","CRSP","QID","CRBU"],"gpt_icon":1},{"id":"2479750708","title":"Galapagos Reports Third Quarter 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2479750708","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479750708?lang=en_us&edition=fundamental","pubTime":"2024-10-31 04:01","pubTimestamp":1730318460,"startTime":"0","endTime":"0","summary":"We are advancing our pipeline and accelerating innovation through focused execution of our Forward, Faster strategy.We are committed to addressing the high unmet needs of patients through a growing cell therapy and small molecule pipeline with breakthrough potential. This includes more than 20 programs, with four assets in clinical development across 11 indications, and more than 15 preclinical programs in oncology and immunology.As part of our collaboration agreement with Blood Centers of America , we selected Excellos in the San Diego area as the first decentralized manufacturing unit  within BCA’s nationwide network to manufacture GLPG5101 for the ATALANTA-1 study sites in the region.Mechelen, Belgium; October 30, 2024, 21:01 CET; regulated information – Galapagos NV  today announced financial results for the first nine months of 2024 and provided a business update.“With more than 20 active cell therapy and small molecule programs in oncology and immunology, we are accelerating our ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/aIgoKEpCU4miJJgLiiqeLg--~B/aD05Mzg7dz01MDk3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/27744832f947e91d201e1a07d1998d59","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/aIgoKEpCU4miJJgLiiqeLg--~B/aD05Mzg7dz01MDk3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/27744832f947e91d201e1a07d1998d59"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/galapagos-reports-third-quarter-2024-200100308.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4546","SLE","GLPG","DM","BK4077","CTA","BK4109","LU2463526074.USD","BK4161","ASH"],"gpt_icon":1},{"id":"2479266414","title":"BRIEF-Super League Completes Initial Stage Of Equity Exchange Transfer With Infinite Reality","url":"https://stock-news.laohu8.com/highlight/detail?id=2479266414","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479266414?lang=en_us&edition=fundamental","pubTime":"2024-10-30 06:08","pubTimestamp":1730239730,"startTime":"0","endTime":"0","summary":"Oct 29 (Reuters) - Super League Enterprise Inc   :   * SUPER LEAGUE COMPLETES INITIAL STAGE OF EQUITY EXCHANGE TRANSFER WITH INFINITE REALITYSource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","BK4588","EQR","BK4585","SSI","BK4215","BK4077"],"gpt_icon":0},{"id":"2479925003","title":"Super League Enterprise announces iR acquires 1.22M shares of common stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2479925003","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479925003?lang=en_us&edition=fundamental","pubTime":"2024-10-30 04:55","pubTimestamp":1730235313,"startTime":"0","endTime":"0","summary":"Super League Enterprise (SLE) announced that, as an initial step in the previously announced equity exchange transfer, Infinite Reality, or iR, has...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/super-league-enterprise-announces-ir-acquires-1-22m-shares-of-common-stock?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/super-league-enterprise-announces-ir-acquires-1-22m-shares-of-common-stock?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLE","BK4077"],"gpt_icon":0},{"id":"2479524382","title":"Super League Completes Initial Stage of Equity Exchange Transfer With Infinite Reality","url":"https://stock-news.laohu8.com/highlight/detail?id=2479524382","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479524382?lang=en_us&edition=fundamental","pubTime":"2024-10-30 04:38","pubTimestamp":1730234321,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241029:nFWN3M51DL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4077","SLE"],"gpt_icon":0},{"id":"2478980885","title":"BRIEF-Super League Announces $1 Mln Registered Direct Investment From Infinite Reality","url":"https://stock-news.laohu8.com/highlight/detail?id=2478980885","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478980885?lang=en_us&edition=fundamental","pubTime":"2024-10-25 21:15","pubTimestamp":1729862122,"startTime":"0","endTime":"0","summary":"Oct 25 (Reuters) - Super League Enterprise Inc   :   * SUPER LEAGUE ANNOUNCES $1 MILLION REGISTERED DIRECT INVESTMENT FROM INFINITE REALITYSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","BK4077"],"gpt_icon":0},{"id":"2478981142","title":"Super League Enterprise announces $1M direct investment from Infinite Reality","url":"https://stock-news.laohu8.com/highlight/detail?id=2478981142","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478981142?lang=en_us&edition=fundamental","pubTime":"2024-10-25 20:21","pubTimestamp":1729858874,"startTime":"0","endTime":"0","summary":"Super League Enterprise (SLE) announced Infinite Reality has made a $1 million registered direct investment in Super League. Ann Hand, Chair and CE...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/super-league-enterprise-announces-1m-direct-investment-from-infinite-reality?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/super-league-enterprise-announces-1m-direct-investment-from-infinite-reality?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4077","SLE"],"gpt_icon":0},{"id":"2478989388","title":"Super League Announces $1 Million Registered Direct Investment From Infinite Reality","url":"https://stock-news.laohu8.com/highlight/detail?id=2478989388","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478989388?lang=en_us&edition=fundamental","pubTime":"2024-10-25 20:00","pubTimestamp":1729857603,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241025:nTUA3XPP1L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLE","BK4077"],"gpt_icon":0},{"id":"2478552989","title":"Press Release: Super League Announces $1 Million Registered Direct Investment From Infinite Reality","url":"https://stock-news.laohu8.com/highlight/detail?id=2478552989","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478552989?lang=en_us&edition=fundamental","pubTime":"2024-10-25 20:00","pubTimestamp":1729857600,"startTime":"0","endTime":"0","summary":"SANTA MONICA, Calif., Oct. 25, 2024  -- Super League Enterprise, Inc. , a global leader in redefining the gaming industry as a media channel, announced today that Infinite Reality , an innovation company powering the next generation of digital media and e-commerce through artificial intelligence , spatial computing, extended reality , and other immersive technologies, has made a $1 million registered direct investment in Super League.Ann Hand, Chair and CEO of Super League, commented, \"We are thrilled to build upon our already strong relationship with the Infinite Reality team and receive this additional vote of confidence and direct investment into Super League. As we enter this strategic partnership with Infinite Reality, we are excited to leverage the components of our respective businesses to provide a unique blend of technologies that broaden our portfolio of audience-based assets.\". \"Our $1 million investment in Super League was the next logical strategic step in solidifying our ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4555","SLE","BK4077","03160","TM","BK4588","BK4099"],"gpt_icon":0},{"id":"2478625486","title":"ImmuneOnco Biopharma SLC Drug Administered to First Patient in Clinical Trial; Shares Up 16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478625486","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478625486?lang=en_us&edition=fundamental","pubTime":"2024-10-25 12:48","pubTimestamp":1729831707,"startTime":"0","endTime":"0","summary":"ImmuneOnco Biopharmaceuticals   said the first patient in its Phase I-B clinical trial for systemic lupus erythematosus  was administered with the dose of treatment, according to a Thursday filing with the Hong Kong bourse.IMM0306 attaches to two specific proteins, CD47 and CD20, found on cancerous B cells and sticks more to CD20 than to CD47, making the cancer treatment more effective, the filing said.The pharma company's shares were up by over 16%.Price : $7.25, Change: $+1.0, Percent Change: +16.19%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","BK4077","BK4023","BK4585","01541","BK4588","HKD","SLE","BK4526"],"gpt_icon":0},{"id":"2477631890","title":"ImmuneOnco Biopharmaceuticals Advances with SLE Treatment Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2477631890","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477631890?lang=en_us&edition=fundamental","pubTime":"2024-10-24 21:40","pubTimestamp":1729777249,"startTime":"0","endTime":"0","summary":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (HK:1541) has released an update. ImmuneOnco Biopharmaceuticals has announced the successful d...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/immuneonco-biopharmaceuticals-advances-with-sle-treatment-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/immuneonco-biopharmaceuticals-advances-with-sle-treatment-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4077","SLE"],"gpt_icon":0},{"id":"2477090667","title":"Biogen Inc. (BIIB): An Oversold Large Cap Stock To Buy Now","url":"https://stock-news.laohu8.com/highlight/detail?id=2477090667","media":"Insider Monkey","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477090667?lang=en_us&edition=fundamental","pubTime":"2024-10-21 04:28","pubTimestamp":1729456091,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 10 Oversold Large Cap Stocks To Buy Now.In this article, we are going to take a look at where Biogen Inc.  stands against the other oversold large cap stocks.The Fed recently reduced the funds rate by 50 basis points, a decision seen as daring by some analysts, though it has been largely embraced by the market and many experts. The market seems to be on an upward trajectory since the day of rate cuts as the S&P gained over 4.3% on October 14 and closed at another all-time high.“Dominic Chu of CNBC expressed concerns about potential market overconfidence, given the calmness amid geopolitical risks, the upcoming U.S. presidential election, and consumer spending challenges. [Gunjan] Banerji acknowledged these risks but emphasized that much of the market’s optimism is tied to the Fed’s actions, with people reassured by the larger-than-expected rate cut.To list 10 oversold large-cap stocks, we used a Finviz","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/kwPLJDk7Luq5fNkaxqHOIQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/8095fdfd16ed3bef236befbd7ca2428c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/kwPLJDk7Luq5fNkaxqHOIQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/8095fdfd16ed3bef236befbd7ca2428c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biogen-inc-biib-oversold-large-202811740.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MNQmain","SQQQ","US12M.BOND","QLD","LU0314104364.USD","LU2357305700.SGD","TQQQ","US6M.BOND","US2Y.BOND","LU0098860793.USD","LU0320765646.SGD","LU1162221912.USD","LU1989772923.USD","QID","AMR","LU0320765992.SGD","BK4585","LU0106831901.USD","LU1720051017.SGD","IE00B19Z9Z06.USD","BK4006","BK4127","IE00BKVL7J92.USD","BK4532","LU1668664300.SGD","US30Y.BOND","US3Y.BOND","BK4504","LU0971096721.USD","BK4533","NQmain","BK4588","BIIB","IE00B894F039.SGD","LU1363072403.SGD","US7Y.BOND","IE00BZ1G4Q59.USD","LU0225283273.USD",".IXIC","US10Y.BOND","LU0234570918.USD","LU0267386448.USD","LU1720051108.HKD","PSQ","BK4581","US5Y.BOND","LU0109394709.USD","US912797HE00.BOND","SLE"],"gpt_icon":1},{"id":"2477049000","title":"Mega-projects like Changi Airport T5 could drive up construction costs in S’pore next year: Surbana Jurong","url":"https://stock-news.laohu8.com/highlight/detail?id=2477049000","media":"Jovi Ho","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477049000?lang=en_us&edition=fundamental","pubTime":"2024-10-20 12:30","pubTimestamp":1729398615,"startTime":"0","endTime":"0","summary":"Surbana Jurong says mechanical and electrical (M&E) costs are set to increase by between 15% and 20% in the remainder of 2024. ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theedgesingapore.com/news/construction/mega-projects-changi-airport-t5-could-drive-construction-costs-spore-next-year?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"edge_highlight","symbols":["BK4077","BK6045","GFA","BK4145","SJ","SLE","MEI","BK4108","BK6520","5OC.SI"],"gpt_icon":0},{"id":"2476829844","title":"Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside","url":"https://stock-news.laohu8.com/highlight/detail?id=2476829844","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476829844?lang=en_us&edition=fundamental","pubTime":"2024-10-18 02:32","pubTimestamp":1729189931,"startTime":"0","endTime":"0","summary":"HC Wainwright has initiated coverage on Alumis Inc. , a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated diseases.Alumis’ lead drug candidate, ESK-001, is a Tyrosine Kinase 2  inhibitor currently in Phase 3 trials for moderate-to-severe plaque psoriasis  and in Phase 2 trials for systemic lupus erythematosus . HC Wainwright analyst has initiated coverage on Alumis with a Buy rating and a price target of $30.Also Read: Newly-Listed Psoriasis-Focused Alumis Attracts Analysts’ Attention With Promising Lead Program And Modest Valuation.According to HC Wainwright, ESK-001 boasts the highest selectivity within the TYK2 inhibitor space, outperforming Bristol Myers Squibb & Co’s  approved drug, Sotyktu  and Takeda Pharmaceutical Co Ltd’s  Phase 3 candidate, TAK-279.While Sotyktu currently leads the TYK2 market, HC Wainwright emphasizes that clinical data for ESK-001 suggest a significantly superior profile, which could drive substantial growth in the TYK2 ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/dhcNQjHv6E4p246dydUpYw--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/7b0670e7da8c4cb8c5e36ff60eee0742","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/dhcNQjHv6E4p246dydUpYw--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/7b0670e7da8c4cb8c5e36ff60eee0742"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alumis-investigational-lead-candidate-supports-183211063.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1093756325.SGD","LU0321505868.SGD","BK4532","LU0321505439.SGD","IE0002141913.USD","LU0225284248.USD","MYE","LU0114720955.EUR","IE0009355771.USD","LU0985481810.HKD","LU0225771236.USD","LU1989771016.USD","BK4126","LU2125154778.USD","LU1670710661.SGD","LU1032466523.USD","LU1670711040.USD","LU0456855351.SGD","LU1291159041.SGD","LU1585245621.USD","BK4581","LU2242646821.SGD","TAK","IE00BJT1NW94.SGD","BK4534","BK4588","LU2242652126.USD","BMY","LU2125154935.USD","IE00B2B36J28.USD","LU0882574055.USD","LU1670710588.SGD","BK4585","LU2360032135.SGD","IE00BFTCPJ56.SGD","LU1074936037.SGD","LU1093756168.USD","BK4077","BK4007","LU0306806265.USD","LU0306807586.USD","ALMS","LU1718418525.SGD","SLE","LU0868494617.USD","LU0061475181.USD","LU1261432733.SGD","LU1670711123.USD","LU2133065610.SGD","LU1571399168.USD"],"gpt_icon":0},{"id":"2476827614","title":"Autolus Therapeutics (AUTL): High-Growth UK Stock in Cancer Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2476827614","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476827614?lang=en_us&edition=fundamental","pubTime":"2024-10-18 02:29","pubTimestamp":1729189766,"startTime":"0","endTime":"0","summary":"We recently published a list of 8 High Growth UK Stocks to Invest In. In this article, we are going to take a look at where Autolus Therapeutics  stands against other high growth UK stocks to invest in.UK inflation is forecasted to rise to 3% by early 2025, after dropping below 2%, this increase is attributed to the ongoing economic recovery and the impact of interest rate cuts on the economy. The Bank of England is expected to take a cautious approach to easing monetary policy, with the base rate expected to reach 3.5% by the end of 2025. This indicates that the central bank will be careful not to overstimulate the economy, in order to avoid overheating and inflationary pressures.Hechler-Fayd’herbe highlights the sector composition of the UK equity market as a key factor in its appeal. The market’s exposure to the energy sector, combined with its relatively lower volatility and higher dividend yields compared to European equities, makes it an attractive investment opportunity. She als","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/sGq5hqUFHDTFnHtiG61VVw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/70ceaa5de4718d95e4b3569a7730ea5d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/sGq5hqUFHDTFnHtiG61VVw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/70ceaa5de4718d95e4b3569a7730ea5d"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/autolus-therapeutics-autl-high-growth-182926261.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4077","TQQQ","NQmain","PSQ","AUTL",".IXIC","QID","SLE","BK4139","MNQmain","QLD","SQQQ"],"gpt_icon":1}],"pageSize":20,"totalPage":7,"pageCount":6,"totalSize":130}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SLE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-28","symbol":"SLE","fiscalQuarterEnding":"2024/12","expectedEps":-0.35,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743134400000,"reportTimeType":"pre","actualEps":-0.45},{"market":"US","date":"2024-11-14","symbol":"SLE","fiscalQuarterEnding":"2024/09","expectedEps":-0.28,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731560400000,"reportTimeType":"post","actualEps":-0.54},{"market":"US","date":"2024-08-14","symbol":"SLE","fiscalQuarterEnding":"2024/06","expectedEps":-0.62,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"post","actualEps":-0.6},{"market":"US","date":"2024-05-15","symbol":"SLE","fiscalQuarterEnding":"2024/03","expectedEps":-1.18,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715745600000,"reportTimeType":"post","actualEps":1},{"market":"US","date":"2024-03-27","symbol":"SLE","fiscalQuarterEnding":"2023/12","expectedEps":-1.23,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1711512000000,"reportTimeType":"post","actualEps":-3.47}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SLE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SLE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1694059200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SLE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SLE","date":"2025-04-01","current":-0.158489,"percent":0.881868,"low":-0.555206,"twenty":-0.344958,"median":-0.284299,"eighty":-0.210038,"high":-0.044016,"avg":-0.275519,"sd":0.108277,"marketCap":3902156},"quantilePoints":[{"date":"2023-09-15","current":-0.077235,"twenty":-0.086128,"median":-0.080205,"eighty":-0.078423,"marketCap":6401787},{"date":"2023-09-22","current":-0.075989,"twenty":-0.079611,"median":-0.075989,"eighty":-0.069678,"marketCap":6298532},{"date":"2023-09-29","current":-0.074744,"twenty":-0.077567,"median":-0.075367,"eighty":-0.07167,"marketCap":6195277},{"date":"2023-10-06","current":-0.072252,"twenty":-0.076986,"median":-0.074328,"eighty":-0.071255,"marketCap":5988768},{"date":"2023-10-13","current":-0.056058,"twenty":-0.075906,"median":-0.072252,"eighty":-0.068681,"marketCap":4646458},{"date":"2023-10-20","current":-0.059795,"twenty":-0.075491,"median":-0.072252,"eighty":-0.064944,"marketCap":4956222},{"date":"2023-10-27","current":-0.044846,"twenty":-0.075325,"median":-0.071006,"eighty":-0.062951,"marketCap":3717166},{"date":"2023-11-03","current":-0.051075,"twenty":-0.07491,"median":-0.068931,"eighty":-0.055726,"marketCap":4233439},{"date":"2023-11-10","current":-0.053151,"twenty":-0.074494,"median":-0.066439,"eighty":-0.051324,"marketCap":4405530},{"date":"2023-11-17","current":-0.15932,"twenty":-0.07491,"median":-0.066023,"eighty":-0.051324,"marketCap":5300404},{"date":"2023-11-24","current":-0.213857,"twenty":-0.076737,"median":-0.067685,"eighty":-0.052154,"marketCap":7114796},{"date":"2023-12-01","current":-0.221494,"twenty":-0.122932,"median":-0.069346,"eighty":-0.053317,"marketCap":7368896},{"date":"2023-12-08","current":-0.2024,"twenty":-0.203928,"median":-0.072252,"eighty":-0.053898,"marketCap":6733646},{"date":"2023-12-15","current":-0.235497,"twenty":-0.21182,"median":-0.072252,"eighty":-0.054563,"marketCap":7834746},{"date":"2023-12-22","current":-0.217675,"twenty":-0.215894,"median":-0.074536,"eighty":-0.054978,"marketCap":7241846},{"date":"2023-12-29","current":-0.203673,"twenty":-0.216403,"median":-0.075159,"eighty":-0.055227,"marketCap":6775996},{"date":"2024-01-05","current":-0.2024,"twenty":-0.216403,"median":-0.075782,"eighty":-0.055726,"marketCap":6733646},{"date":"2024-01-12","current":-0.210038,"twenty":-0.216403,"median":-0.07765,"eighty":-0.056058,"marketCap":6987746},{"date":"2024-01-19","current":-0.220221,"twenty":-0.217675,"median":-0.090076,"eighty":-0.057553,"marketCap":7326546},{"date":"2024-01-26","current":-0.238043,"twenty":-0.218439,"median":-0.176404,"eighty":-0.060459,"marketCap":7919446},{"date":"2024-02-02","current":-0.263515,"twenty":-0.222258,"median":-0.2024,"eighty":-0.062452,"marketCap":8766869},{"date":"2024-02-09","current":-0.288961,"twenty":-0.22404,"median":-0.203673,"eighty":-0.064279,"marketCap":9613445},{"date":"2024-02-16","current":-0.328423,"twenty":-0.227604,"median":-0.204946,"eighty":-0.06511,"marketCap":10926294},{"date":"2024-02-23","current":-0.31442,"twenty":-0.235497,"median":-0.207492,"eighty":-0.065774,"marketCap":10460445},{"date":"2024-03-01","current":-0.306782,"twenty":-0.258166,"median":-0.208765,"eighty":-0.066522,"marketCap":10206345},{"date":"2024-03-08","current":-0.254591,"twenty":-0.26656,"median":-0.210038,"eighty":-0.067186,"marketCap":8469996},{"date":"2024-03-15","current":-0.225313,"twenty":-0.263003,"median":-0.213857,"eighty":-0.068681,"marketCap":7495946},{"date":"2024-03-22","current":-0.349526,"twenty":-0.275749,"median":-0.21513,"eighty":-0.069346,"marketCap":11628396},{"date":"2024-03-28","current":-0.4417,"twenty":-0.283869,"median":-0.216403,"eighty":-0.069346,"marketCap":13396770},{"date":"2024-04-05","current":-0.367495,"twenty":-0.286708,"median":-0.217039,"eighty":-0.071006,"marketCap":11146112},{"date":"2024-04-12","current":-0.300356,"twenty":-0.297872,"median":-0.218948,"eighty":-0.072252,"marketCap":9109803},{"date":"2024-04-19","current":-0.288,"twenty":-0.297872,"median":-0.220857,"eighty":-0.072252,"marketCap":8735051},{"date":"2024-04-26","current":-0.293245,"twenty":-0.295326,"median":-0.222767,"eighty":-0.072252,"marketCap":8894120},{"date":"2024-05-03","current":-0.294239,"twenty":-0.295326,"median":-0.22404,"eighty":-0.072252,"marketCap":8924269},{"date":"2024-05-10","current":-0.276346,"twenty":-0.294239,"median":-0.22404,"eighty":-0.073498,"marketCap":8381577},{"date":"2024-05-17","current":-0.295605,"twenty":-0.295605,"median":-0.227222,"eighty":-0.074328,"marketCap":8381577},{"date":"2024-05-24","current":-0.265832,"twenty":-0.295326,"median":-0.232951,"eighty":-0.074744,"marketCap":7537390},{"date":"2024-05-31","current":-0.292406,"twenty":-0.294456,"median":-0.235497,"eighty":-0.075076,"marketCap":8290883},{"date":"2024-06-07","current":-0.271353,"twenty":-0.294239,"median":-0.238043,"eighty":-0.075491,"marketCap":7693940},{"date":"2024-06-14","current":-0.252339,"twenty":-0.293643,"median":-0.245044,"eighty":-0.075823,"marketCap":7154833},{"date":"2024-06-21","current":-0.201872,"twenty":-0.292909,"median":-0.238043,"eighty":-0.076487,"marketCap":5723866},{"date":"2024-06-28","current":-0.196825,"twenty":-0.292574,"median":-0.238043,"eighty":-0.076986,"marketCap":5580762},{"date":"2024-07-05","current":-0.214489,"twenty":-0.291076,"median":-0.236984,"eighty":-0.077484,"marketCap":6081608},{"date":"2024-07-12","current":-0.257386,"twenty":-0.29019,"median":-0.238043,"eighty":-0.079183,"marketCap":7297929},{"date":"2024-07-15","current":-0.26748,"twenty":-0.29019,"median":-0.238043,"eighty":-0.079694,"marketCap":7584122},{"date":"2024-08-02","current":-0.322994,"twenty":-0.29019,"median":-0.238043,"eighty":-0.080205,"marketCap":9158186},{"date":"2024-08-09","current":-0.280097,"twenty":-0.291452,"median":-0.25,"eighty":-0.090076,"marketCap":7941864},{"date":"2024-08-16","current":-0.331284,"twenty":-0.291452,"median":-0.254591,"eighty":-0.144836,"marketCap":7941864},{"date":"2024-08-23","current":-0.53758,"twenty":-0.294239,"median":-0.257262,"eighty":-0.15932,"marketCap":12887411},{"date":"2024-08-30","current":-0.506735,"twenty":-0.296227,"median":-0.259657,"eighty":-0.193489,"marketCap":12147969},{"date":"2024-09-06","current":-0.478094,"twenty":-0.298215,"median":-0.261996,"eighty":-0.196158,"marketCap":11461345},{"date":"2024-09-13","current":-0.387888,"twenty":-0.305764,"median":-0.26512,"eighty":-0.200267,"marketCap":9298829},{"date":"2024-09-20","current":-0.279367,"twenty":-0.307264,"median":-0.267321,"eighty":-0.201723,"marketCap":6697270},{"date":"2024-09-27","current":-0.280954,"twenty":-0.305764,"median":-0.2674,"eighty":-0.201872,"marketCap":6735311},{"date":"2024-10-04","current":-0.340548,"twenty":-0.30919,"median":-0.267958,"eighty":-0.202294,"marketCap":8163949},{"date":"2024-10-11","current":-0.449597,"twenty":-0.311325,"median":-0.268116,"eighty":-0.2024,"marketCap":10778189},{"date":"2024-10-18","current":-0.388813,"twenty":-0.315693,"median":-0.269014,"eighty":-0.203418,"marketCap":9321020},{"date":"2024-10-25","current":-0.405078,"twenty":-0.328743,"median":-0.270264,"eighty":-0.203673,"marketCap":9710936},{"date":"2024-10-31","current":-0.447393,"twenty":-0.331576,"median":-0.271783,"eighty":-0.204227,"marketCap":10725354},{"date":"2024-11-08","current":-0.410367,"twenty":-0.346526,"median":-0.273854,"eighty":-0.204806,"marketCap":9837739},{"date":"2024-11-15","current":-0.436374,"twenty":-0.369724,"median":-0.275294,"eighty":-0.204946,"marketCap":10461183},{"date":"2024-11-22","current":-0.261371,"twenty":-0.368039,"median":-0.276231,"eighty":-0.20571,"marketCap":6435212},{"date":"2024-11-29","current":-0.294604,"twenty":-0.364668,"median":-0.276346,"eighty":-0.206728,"marketCap":7253456},{"date":"2024-12-06","current":-0.323013,"twenty":-0.356067,"median":-0.277855,"eighty":-0.207492,"marketCap":7952897},{"date":"2024-12-13","current":-0.312281,"twenty":-0.347526,"median":-0.28005,"eighty":-0.208001,"marketCap":7688663},{"date":"2024-12-20","current":-0.321435,"twenty":-0.346138,"median":-0.280097,"eighty":-0.208765,"marketCap":7914039},{"date":"2024-12-27","current":-0.339269,"twenty":-0.34373,"median":-0.28052,"eighty":-0.20902,"marketCap":8353132},{"date":"2025-01-03","current":-0.336691,"twenty":-0.344526,"median":-0.281632,"eighty":-0.210038,"marketCap":8289664},{"date":"2025-01-10","current":-0.383512,"twenty":-0.351706,"median":-0.282822,"eighty":-0.210038,"marketCap":9442446},{"date":"2025-01-17","current":-0.309808,"twenty":-0.347717,"median":-0.284299,"eighty":-0.211096,"marketCap":7627786},{"date":"2025-01-24","current":-0.310545,"twenty":-0.347233,"median":-0.284972,"eighty":-0.212858,"marketCap":7645920},{"date":"2025-01-31","current":-0.354781,"twenty":-0.353001,"median":-0.285142,"eighty":-0.213857,"marketCap":8735057},{"date":"2025-02-07","current":-0.319937,"twenty":-0.350441,"median":-0.285388,"eighty":-0.213857,"marketCap":7877163},{"date":"2025-02-14","current":-0.31412,"twenty":-0.349224,"median":-0.286351,"eighty":-0.213857,"marketCap":7733942},{"date":"2025-02-21","current":-0.308303,"twenty":-0.349022,"median":-0.286674,"eighty":-0.21411,"marketCap":7590720},{"date":"2025-02-28","current":-0.232681,"twenty":-0.348999,"median":-0.28664,"eighty":-0.214489,"marketCap":5728846},{"date":"2025-03-07","current":-0.21936,"twenty":-0.348284,"median":-0.285948,"eighty":-0.214489,"marketCap":5400869},{"date":"2025-03-14","current":-0.209704,"twenty":-0.347244,"median":-0.285144,"eighty":-0.213941,"marketCap":5163122},{"date":"2025-03-21","current":-0.201444,"twenty":-0.347002,"median":-0.285098,"eighty":-0.212359,"marketCap":4959748},{"date":"2025-03-28","current":-0.230354,"twenty":-0.345822,"median":-0.284304,"eighty":-0.212359,"marketCap":5671557},{"date":"2025-04-01","current":-0.158489,"twenty":-0.344958,"median":-0.284299,"eighty":-0.210038,"marketCap":3902156}],"updateTime":1743659169869}}}